Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.58 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.53 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089195 | 1.00 | ADORA2A (0.80) | ADORA2AADORA3ADORA1PRMT5METTL3 | |
| SCHEMBL10456342 | 0.95 | ADORA2A (0.80) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL14367724 | 0.95 | ADORA2A (0.80) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL10455994 | 0.94 | ADORA2A (0.76) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13612127 | 0.94 | ADORA2A (0.76) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL12547192 | 0.94 | ADORA2A (0.78) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13020932 | 0.94 | ADORA2A (0.78) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL8922576 | 0.94 | ADORA2A (0.78) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL10456127 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13612217 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | The Regents of the University of Colorado, a body corporation (US) | 2013-05-16 | — | — | US | disclosed |
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-7989431-B2 | 4-{3-[6-Amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester; for inflammation, such as organ, tissue or cell transplantation, angioplasty (PCTA), inflammation following ischemia/reperfusion, or grafting | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-11-12 | — | — | US | disclosed |
| US-7605143-B2 | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090253647-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION AND ADENOSINE THERAPEUTICS, L.L.C. | 2009-10-08 | — | — | US | disclosed |
| US-20090181920-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-07-16 | — | — | US | disclosed |
| US-20080312160-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-12-18 | — | — | US | disclosed |
| US-20080262001-A1 | a 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid ester | ADENOSINE THERAPEUTICS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
| US-7378400-B2 | Method to reduce an inflammatory response from arthritis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-05-27 | — | — | US | disclosed |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-03-13 | — | — | US | disclosed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885ADORA3 1/4885ADORA1 4/4885 |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 4/4885 |
| US-20080262001-A1 | a 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid ester | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA1 4/4885 |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | ADORA2A, ADORA2B, PDE4A | ADORA2A 1/4885ADORA3 4/4885ADORA1 10/4885 |
| US-20090253647-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20080312160-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | ADORA2A, ADORA3, GLUL | ADORA2A 1/4885ADORA3 2/4885ADORA1 6/4885 |
| US-20090181920-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.